Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies biomarkers in blood and tissue samples from patients with Epstein-Barr virus positive Hodgkin lymphoma.

Detailed Description
-----------------
OBJECTIVES: Evaluate germline DNA from patients with Epstein-Barr virus positive (EBV+) and Hodgkin lymphoma (HL) for inducible T-cell kinase (ITK) mutations. Examine the effects of ITK mutations on expression of the ITK protein. Determine whether ITK mutations correlate with specific clinical or histopathological features of HL. OUTLINE: Archived blood and tumor tissue samples are analyzed for germline DNA expression and inducible T-cell kinase (ITK) mutations by PCR, IHC, flow cytometry, and western blotting, and EBV-encoded RNA (EBER) using in situ hybridization. Each patient's data, such as date, sex, age, tumor stage and histology at diagnosis, treatment received, response to treatment, development of recurrent disease, date of last follow-up, and outcomes are also collected.

Official Title
-----------------
Role of the IL-2 Inducible Tcell Kinase in EBV-HLH and EBV+ Hodgkin's Lymphoma

Conditions
-----------------
Lymphoma, Nonneoplastic Condition

Intervention / Treatment
-----------------
* Genetic: DNA analysis
* Genetic: RNA analysis
* Genetic: cytogenetic analysis
* Genetic: in situ hybridization
* Genetic: mutation analysis
* Genetic: polymerase chain reaction
* Genetic: western blotting
* Other: flow cytometry
* Other: immunohistochemistry staining method
* Other: medical chart review


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of Hodgkin lymphoma (HL) meeting the following criteria: Epstein-Barr virus-positive (EBV+) HL as assessed by positive EBV serology, elevated levels of EBV genome in the blood or tumor tissue following quantitative polymerase chain reaction (PCR) and/or evidence of EBV positivity of pathology samples (EBER+ or LMP+) and, when possible, mixed cellular histology Young age (< 10 years) at diagnosis Presence of hemophagocytic lymphohistiocytosis (HLH) PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: DNA analysis|nan|
|Genetic: RNA analysis|nan|
|Genetic: cytogenetic analysis|nan|
|Genetic: in situ hybridization|nan|
|Genetic: mutation analysis|nan|
|Genetic: polymerase chain reaction|nan|
|Genetic: western blotting|nan|
|Other: flow cytometry|nan|
|Other: immunohistochemistry staining method|nan|
|Other: medical chart review|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of germline ITK mutations |  |  | 
| Influence of ITK mutations on total expression levels or intracellular localization of the ITK protein |  |  | 
| Correlation between ITK mutations with specific clinical or histopathological features of HL |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
childhood Hodgkin lymphoma, childhood mixed cellularity Hodgkin lymphoma, hemophagocytic lymphohistiocytosis, Epstein-Barr virus infection